Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751527 | 1.00 | MCL1 (0.49) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL16936484 | 0.98 | MCL1 (0.47) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL11517543 | 0.94 | MCL1 (0.42) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL4745209 | 0.80 | MCL1 (0.49) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL182225 | 0.79 | MAPK1 (0.50) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL63339 | 0.77 | MCL1 (0.53) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL1132452 | 0.76 | MCL1 (0.45) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL28485927 | 0.76 | CCR2 (0.44) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL6914585 | 0.75 | MCL1 (0.52) | MCL1MAPK1CA1CA2CA4 | |
| SCHEMBL11664151 | 0.75 | MCL1 (0.52) | MCL1MAPK1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 605 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119662037-A | Preparation method of blue dye | 沈阳化工研究院有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-12122788-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | claimed |
| CN-117304184-A | Pyrrolo [2,3-b ] pyridine intermediate compound and preparation method and application thereof | 南京羚诺生物医药技术研究院有限公司 | 2023-12-29 | — | — | CN | claimed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | claimed |
| CN-115197195-A | Preparation method of flumatinib intermediate | 江苏豪森药业集团有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-111592490-B | Preparation method of key intermediate of roxasistat | 浙江工业大学 | 2022-04-22 | — | — | CN | claimed |
| US-20210246117-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-08-12 | — | — | US | claimed |
| CN-110183452-B | Perfluorobutyl substituted compound and preparation method and application thereof | 中山大学 | 2021-06-01 | — | — | CN | claimed |
| CN-112830893-A | ROR gamma inhibitor, preparation method and medical application thereof | 成都倍特药业股份有限公司 | 2021-05-25 | — | — | CN | claimed |
| EP-3720849-A2 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2020-10-14 | — | — | EP | claimed |
| US-20140051867-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | claimed |
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | claimed |
| EP-2540711-A1 | SELENALZOLE DERIVATIVE HAVING LIGAND WHICH ACTIVATES PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR), PREPARING METHOD THEREOF AND USAGE OF THE CHEMICAL COMPOUNDS | SNU R & DB Foundation (KR) | 2013-01-02 | — | — | EP | claimed |
| US-20120316346-A1 | SELENALZOLE DERIVATIVE HAVING LIGAND WHICH ACTIVATES PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR), PREPARING METHOD THEREOF AND USAGE OF THE CHEMICAL COMPOUNDS | SNU R & DB FOUNDATION (KR) | 2012-12-13 | — | — | US | claimed |
| US-20110183079-A1 | PLASMA ENHANCED ATOMIC LAYER DEPOSITION PROCESS | PENN STATE RESEARCH FOUNDATION (US) | 2011-07-28 | — | — | US | claimed |
| WO-2011026064-A1 | IMPROVED PLASMA ENHANCED ATOMIC LAYER DEPOSITION PROCESS | THE PENN STATE RESEARCH FOUNDATION (US) | 2011-03-03 | — | — | WO | claimed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | claimed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | claimed |
| WO-2007134421-A1 | 2-VINYL INDOLES, PYRIDO AND AZEPINO INDOLE DERIVATIVES, 2-ALKYNYL INDOLES, 2-ALKYNYL BENZO[b]FURANS, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2007-11-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | MCL1 3767/4885MAPK1 2836/4885CA1 4856/4885 |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | MCL1 4637/4885MAPK1 2582/4885CA1 1235/4885 |
| US-20210246117-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | MCL1 4101/4885MAPK1 1948/4885CA1 4860/4885 |
| US-20120316346-A1 | SELENALZOLE DERIVATIVE HAVING LIGAND WHICH ACTIVATES PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR), PREPARING METHOD THEREOF AND USAGE OF THE CHEMICAL COMPOUNDS | PPARG, PPARA, PPARD | MCL1 4091/4885MAPK1 1993/4885CA1 4069/4885 |
| US-20140051867-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, SARS1, MAVS | MCL1 1094/4885MAPK1 1915/4885CA1 4610/4885 |
| US-12122788-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | MCL1 3767/4885MAPK1 2836/4885CA1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.